Market Overview

Akorn Shares Rally Following Increased Price Target

Related AKRX
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years
Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.

The note cited a "game changing" effect if Akorn matches Taro Pharmaceutical Industries' recent price increases in topical generics.

Shares are currently up 5.25 percent at $34.99.

Latest Ratings for AKRX

Jun 2015Raymond JamesInitiates Coverage onOutperform
Apr 2015Piper JaffrayDowngradesOverweightNeutral
Apr 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: NeedhamAnalyst Color News Price Target Analyst Ratings


Related Articles (AKRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters